Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
World game at war: why some European nations have threatened a World Cup boycott 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
CAMBRIDGE, Mass., May 01, 2018 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018 and provide a corporate update before the U.S. financial markets open on Tuesday, May 8, 2018.
Management will host a conference call on that date at 8:00 a.m. ET to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 7665388. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]
